FATTIZZO, BRUNO
 Distribuzione geografica
Continente #
EU - Europa 7.870
NA - Nord America 4.612
AS - Asia 2.461
SA - Sud America 472
AF - Africa 81
OC - Oceania 78
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.578
Nazione #
US - Stati Uniti d'America 4.225
DE - Germania 3.710
CN - Cina 1.097
IT - Italia 1.087
GB - Regno Unito 1.044
SE - Svezia 456
IN - India 447
FR - Francia 351
IE - Irlanda 282
JP - Giappone 270
ES - Italia 254
MX - Messico 201
CA - Canada 164
BR - Brasile 115
TR - Turchia 112
AR - Argentina 109
HK - Hong Kong 96
CO - Colombia 87
SG - Singapore 83
ID - Indonesia 75
BE - Belgio 72
CH - Svizzera 71
GR - Grecia 63
NL - Olanda 63
AU - Australia 61
DK - Danimarca 61
CL - Cile 56
KR - Corea 55
PE - Perù 54
RU - Federazione Russa 49
PL - Polonia 44
UA - Ucraina 44
RO - Romania 42
FI - Finlandia 35
TH - Thailandia 32
EG - Egitto 30
PT - Portogallo 29
IR - Iran 28
SA - Arabia Saudita 26
IL - Israele 24
NO - Norvegia 21
AT - Austria 20
MY - Malesia 18
PH - Filippine 18
VN - Vietnam 18
NZ - Nuova Zelanda 17
RS - Serbia 17
EC - Ecuador 16
PK - Pakistan 16
VE - Venezuela 15
TW - Taiwan 13
HU - Ungheria 12
ZA - Sudafrica 11
HR - Croazia 10
UY - Uruguay 10
BO - Bolivia 9
MA - Marocco 9
BG - Bulgaria 7
TN - Tunisia 6
AL - Albania 5
DZ - Algeria 5
ET - Etiopia 5
IQ - Iraq 5
SI - Slovenia 5
EU - Europa 4
GT - Guatemala 4
LK - Sri Lanka 4
MD - Moldavia 4
NI - Nicaragua 4
SC - Seychelles 4
CR - Costa Rica 3
CU - Cuba 3
CZ - Repubblica Ceca 3
EE - Estonia 3
GD - Grenada 3
KW - Kuwait 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
BJ - Benin 2
GE - Georgia 2
JO - Giordania 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LT - Lituania 2
MM - Myanmar 2
MW - Malawi 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
TG - Togo 2
ZW - Zimbabwe 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CW - ???statistics.table.value.countryCode.CW??? 1
GP - Guadalupe 1
KZ - Kazakistan 1
LU - Lussemburgo 1
PS - Palestinian Territory 1
Totale 15.575
Città #
Frankfurt am Main 2.507
Hanover 925
Southend 758
Chandler 584
Milan 348
Princeton 291
Dublin 277
Fairfield 269
Wilmington 215
Ashburn 199
Redwood City 167
Seattle 160
Woodbridge 137
Cambridge 127
Houston 122
Beijing 112
New York 108
Ann Arbor 107
Bengaluru 107
Des Moines 94
Hong Kong 70
Tianjin 67
Shanghai 65
Toronto 65
Paris 61
Dearborn 57
Rome 55
Tokyo 55
Madrid 54
Nanjing 53
Buenos Aires 52
Berlin 51
Duncan 44
Lima 41
Barcelona 40
Jinan 40
Naples 40
Bogotá 39
London 37
Brussels 36
Turin 36
Hangzhou 35
Phoenix 35
Mexico City 32
Santiago 32
São Paulo 32
Seoul 29
Karimnagar 28
San Diego 28
Los Angeles 27
Istanbul 26
Shenyang 26
Sunnyvale 26
Chennai 23
Boston 22
Delhi 22
Helsinki 22
Manchester 22
Mumbai 22
Bühl 21
Guangzhou 21
Singapore 21
Falls Church 20
Roxbury 20
Athens 19
Chengdu 19
Medellín 18
Nanchang 18
Amsterdam 17
Boardman 17
Cairo 17
Changsha 17
Melbourne 17
New Delhi 17
Andover 16
Hyderabad 16
Vienna 16
Bangkok 15
Valencia 15
Florence 14
Izmir 14
Liège 14
Osaka 14
Pittsburgh 14
San Francisco 14
Auckland 13
Bari 13
Bucharest 13
Montreal 13
Ottawa 13
Belgrade 12
Birmingham 12
Bologna 12
Central 12
Chicago 12
Cincinnati 12
Pontedera 12
Redmond 12
Amiens 11
Columbus 11
Totale 9.785
Nome #
How I treat warm autoimmune hemolytic anemia 2.250
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia : a GIMEMA study of 308 Patients 1.140
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers 751
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease : a phase 2 prospective GIMEMA study 380
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome 311
Evidence based use of erytrhopoietin in patients with autoimmune hemolytic anemia: a multicenter international study 283
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag 275
Prognostic and predictive impact of small PNH clones in a large cohort of patients with myelodysplastic syndrome and aplastic anemia: a single-center experience 271
Low-dose rituximab in autoimmune hemolytic anemia : 10 years after 262
Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag 245
Anemia emolitica autoimmune dall’approccio classico ai nuovi farmaci 230
Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias 214
Paroxysmal Nocturnal Hemoglobinuria (Pnh) : Brain Mri Ischemic Lesions in Neurologically Asymtomatic Patients 170
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 165
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects 160
Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy 159
Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report 158
Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications 153
Biological and molecular characterization of a rare case of cutaneous Richter syndrome 149
Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues 147
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia 145
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs 145
Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study 120
Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients 116
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease 112
The Changing Landscape of Autoimmune Hemolytic Anemia 109
Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia 106
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias 105
The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects 100
Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia 100
Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review 98
Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk 96
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review 94
Predictors of atrial fibrillation in ibrutinib-treated CLL patients : a prospective study 92
Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study 91
Anemia and splenomegaly: what lies behind? 91
Evans syndrome in adults : an observational multicenter study 90
Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression 89
Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations 87
Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes : a second honeymoon? 86
Chronic lymphocytic leukemia and prognostic models : a bridge between clinical and biological markers 85
Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia 85
Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation 84
Reduced expression of toll-like receptor 4 in B-chronic lymphocytic leukemia patients with autoimmune complications 84
Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation : current perspectives 82
Chronic Idiopathic Neutropenia In Adults: Clinical Features In a 4-Year Prospective Study 80
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures 78
Three hematologic malignancies in the same patient : chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia 78
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia : clinical efficacy and biologic studies 77
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 77
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia 76
Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study 76
Brain MRI Findings and Neuro-Psychiatric Involvement in Paroxysmal Nocturnal Hemoglobinuria (PNH) 75
Autoimmune hemolytic anemia: clinical severity and laboratory heterogeneity in 157 patients 75
Evidence based use of erytrhopoietin in patients with Autoimmune Hemolytic Anemia : a multicenter international study 74
Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes 74
Impact of intravascular hemolysis and multitreatment on thrombosis occurrence in autoimmune hemolytic anemia 73
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality 73
Neuro-psychiatric involvement in paroxysmal nocturnal hemoglobinuria (PNH) 73
Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia 72
Cold agglutinin disease revisited: a multinational, observational study of 232 patients 71
Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome 71
A Review on Chronic Neutropenia of the Adult: Emerging Clinical Dilemmas 71
Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis 70
Inhibition of C3 with APL-2 controls haemolysis and increases haemoglobin levels in subjects with Autoimmune Haemolytic Anaemia (AIHA) 69
Recent insights into the role of the microbiome in malignant and benign hematologic diseases 69
Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL) 68
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations 68
Anti-erythroblast autoimmunity in early myelodysplastic syndromes: enhancement of EPO/EPO-R system and PRO-apoptotic effect 67
Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group 67
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience 66
Autoimmune hemolytic anemia - progress in emerging treatment options 66
25-Oh Vitamin D, Vitamin D Receptor and Immunomodulatory Cytokines Serum Levels in Patients with Autoimmune Citopenias: Correlation with Hematologic Parameters and Clinical Severity 66
Increased prevalence of autoimmune phenomena in myelofibrosis : relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns 65
Hypoplastic myelodysplastic syndromes: Just an overlap syndrome? 65
Myelofibrosis and following chronic myeloid leukemia: imatinib and ruxolitinib treatment in two cases 64
Clinical Heterogeneity Of Autoimmune Hemolytic Anemia: A 35-Years Retrospective Study Of 157 Patients 64
Are Patients With Autoimmune Cytopenias at Higher Risk of COVID-19 Pneumonia? The Experience of a Reference Center in Northern Italy and Review of the Literature 64
Bortezomib in autoimmune hemolytic anemia and beyond 64
Thrombotic events in myelofibrosis: relationship with clinical and morphological characteristics, JAK2V617F mutational status and autoimmune phenomena 63
Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature 63
Impact of bone marrow fibrosis in response to azacitidine in 94 patients with myelodisplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia 62
Innovative Treatments for Rare Anemias 62
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome 62
Complement Mediated Hemolytic Anemias in the COVID-19 Era : Case Series and Review of the Literature 61
Clinical heterogeneity of autoimmune hemolytic anemia: a gimema study of 308 patients 60
Reduced 25-OH vitamin D levels in patients with autoimmune citopenias: correlation with haematological parameters and clinical severity 60
Aplasie Midollari 60
A case of chronic chronic lymphocytic leukemia developing chronic myeloid leukemia with high platelets and followed by acute myeloid leukemia 60
Expression of TLRs in B-CLL: Relationship with Disease Activity 60
Heminsight to assess patient reported outcomes of patients affected by chronic lymphocytic leukemia in daily clinical practice 60
Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature 60
Autoimmune complications in hematologic neoplasms 60
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia 60
Clinical follow-up of 378 patients with autoimmune hemolytic anemia: prognostic impact of hemoglobin levels, autoantibody class, and reticulocytopenia at onset on the relapse risk and outcome 59
Prevalence and clinical significance of small PNH clones in patiens with primary autoimmune hemolytic anemia 59
Clinical follow-up of 378 patients with autoimmune hemolytic anemia: prognostic impact of hemoglobin levels, autoantibody class, and reticulocytopenia at onset on the relapse risk and outcome 59
A case of severe aplastic anaemia after SARS-CoV-2 vaccination 59
Difficult cases of paroxysmal nocturnal hemoglobinuria: Diagnosis and therapeutic novelties 59
Cell Population Data NE-WX, NE-FSC, LY-Y of Sysmex XN-9000 can provide additional information to differentiate macrocytic anaemia from myelodysplastic syndrome: A preliminary study 59
Totale 14.038
Categoria #
all - tutte 37.665
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.665


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019130 0 0 0 0 0 0 0 0 0 34 35 61
2019/2020519 57 11 27 53 23 71 52 20 97 69 21 18
2020/20212.228 52 195 362 291 146 221 134 207 216 149 125 130
2021/20223.631 112 154 299 221 283 200 229 455 468 357 340 513
2022/20234.019 379 310 299 384 294 548 280 300 409 166 386 264
2023/20245.119 265 272 268 319 582 294 1.101 961 579 478 0 0
Totale 16.294